IQVIA Holdings, Inc. · NYSE:IQV
IQVIA — Quintiles — Morgan Stanley Global Healthcare Conference 2014
19 slides from IQVIA's conference presentation, Sep 8, 2014
Slide 1: Morgan Stanley Global Healthcare Conference
Morgan Stanley Global Healthcare Conference September 8, 2014 NYSE: Q © Copyright 2014 Quintiles
Slide 2: Forward Looking Statements and Use of Non-GAAP Financial Measures
Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements refl
Slide 3: Enterprise Vision and Strategy
Enterprise Vision and Strategy Quintiles We bring people and Vision knowledge together for a healthier world Our Strategic Agenda Profitable growth at above market rates Lead with investments Biopharma Product Integrated that leverage our scale Healthcare Services Development Our Customer Promise an
Slide 4: Track Record of Profitable Growth and Consistency
Track Record of Profitable Growth and Consistency Long term Performance Underpinned with a Diversified Customer Portfolio Adjusted Service Revenues(1) Adjusted EBITDA(2) ’10 – ’13 CAGR = 8.3% ’10 – ’13 CAGR = 9.7% 4,500 700 $663 $3,977 $3,808 (5) $612 4,000 $3,692 600 $544 3,500 $3,295 $490 $2,997 5
Slide 5: Continued Momentum in 2014
Continued Momentum in 2014 Six Months Ended June 30, 2014 FINANCIAL HIGHLIGHTS OTHER HIGHLIGHTS 8.5% Constant Currency Revenue(1) 1.23x Book-to-bill ratio - 7.6% in Product Development - 1.21x in Product Development -11.5% in Integrated Healthcare - 1.29x in Integrated Healthcare Services Services 9
Slide 6: Attractive and Growing Market
Attractive and Growing Market ~$200bn total market across both segments with increasing outsourcing penetration which drives estimated growth of 5% – 8% per year from 2013 – 2016 Product Development Approval Phase Commercial Healthcare Phase I Phase II Phase III IV Delivery Product Development Servi
Slide 7: Evolving Biopharma Landscape
Evolving Biopharma Landscape Growth, inefficiency and complexity play to Quintiles’ strength The median number of procedures per trial increased by 57% between 2003 and 20111 Increasing Trial Complexity R&D spending grew Over 3,000 ongoing clinical trials involve a biomarker or Personalized R&D ~1.5
Slide 8: Deep Customer Relationships
Deep Customer Relationships Largest backlog in industry with diversification and sustainability Worked with all top 20 biopharma companies in each of last 11 years All of our top 25 key customers worked with both Quintiles segments: PD and IHS $100mm+ service revenues from at least 8 customers in ea
Slide 9: The Leader in BioPharma Services
The Leader in BioPharma Services Why We Win = Enhanced Value for Customers • Clearly differentiated service offerings Leader of innovative models > Improving probability of success > Depth and breadth of service offerings > Provided services to develop or commercialize enabled the win of 2 sole prov
Slide 10: Product Development
Product Development Accelerating pipelines using science, technology and global delivery Ph - I Ph - II Ph - III Ph-IIIB & IV Product Development Services • Core Segment representing 75% of Consolidated Service Deep Science, Therapeutic, & Revenues and 93% of Segment Income from Operations(1) Regula
Slide 11: Integrated Healthcare Services
Integrated Healthcare Services Improving the probability of commercial success Phase II & III Commercial Healthcare Delivery Integrated Healthcare Services Offerings Integrated Healthcare Services Commercial Services: • Contract Sales • IHS Segment represents 25% of Consolidated • Market Entry / Mar
Slide 12: An Attractive Investment
Quintiles An Attractive Investment Strong free cash flow Best in industry operating margins with a consistent focus on process and productivity leverage Deep and diverse customer relationships with no customer contributing 10% or more of revenues Long-term consistent financial performance First move
Slide 13: Appendix
Appendix O QUINTILES’ 13
Slide 14: Adjusted Service Revenues Reconciliation
Adjusted Service Revenues Reconciliation Adjusted Service Revenues Reconciliation Year Ended December 31 (In Thousands) Six Months Trailing Twelve 2013 2012 2011 2010 Ended June Months Ended 30, 2014 June 30, 2014 Non-GAAP Adjusted Service Revenues: GAAP Service Revenues as Reported $2,040,764 3,977
Slide 15: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Adjusted EBITDA Reconciliation Year Ended December 31 (In Thousands) Six Months Trailing 12 2013 2012 2011 2010 Ended June Months 30, 2014 Ended June 30, 2014 Non-GAAP Adjusted EBITDA: GAAP Net Income as Reported $175,324 $314,842 $226,027 $176,631 $240,327 $165,255 In
Slide 16: Adjusted Net Income Reconciliation
Adjusted Net Income Reconciliation Adjusted Net Income Reconciliation Year Ended December 31 (In Thousands) Six Months Trailing 12 2013 2012 2011 2010 Ended Months June 30, Ended 2014 June 30, 2014 Non-GAAP Adjusted Net Income: GAAP Net Income as Reported $175,324 $314,842 $226,027 $176,631 $240,327
Slide 17: Income Statement GAAP – Non-GAAP Reconciliation
Income Statement GAAP – Non-GAAP Reconciliation 2014 2013 Selling, Income Net Income Selling, Income Net Income Three Months Ended June 30 General and from Attributable General and from Attributable (millions of dollars) Administrative Operations to Quintiles Administrative Operations to Quintiles A
Slide 18: Constant Currency Reconciliation Service Revenues and Income from Operations
Constant Currency Reconciliation Service Revenues and Income from Operations (millions of dollars) Three Months Ended June 30 Year on Year Growth Exchange Exchange Consolidated Actual Impact Constant Actual Impact Constant Service Revenues $ 1,035.5 $ 10.1 $ 1,025.4 9.7% 1.1% 8.6% Income from Operat
Slide 19: Contractual Revenue Currency Mix and Foreign Exchange Analysis
Contractual Revenue Currency Mix and Foreign Exchange Analysis Consolidated Service Revenues (millions of dollars) USD Sterling Euro Yen Other1 Total 2Q '14 $645.3 $84.3 $169.5 $107.6 $28.8 $1,035.5 % of total 63% 8% 16% 10% 3% 100% 2Q '13 $582.7 $65.1 $161.5 $96.7 $38.2 $944.2 % of total 62% 7% 17%
Quintiles — Morgan Stanley Global Healthcare Conference 2014 on 6ix